Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Regenerative Medical Technology (RMTG) Net Income towards Common Stockholders (2018 - 2025)

Historic Net Income towards Common Stockholders for Regenerative Medical Technology (RMTG) over the last 8 years, with Q3 2025 value amounting to -$3.9 million.

  • Regenerative Medical Technology's Net Income towards Common Stockholders fell 34436.35% to -$3.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.6 million, marking a year-over-year increase of 73.94%. This contributed to the annual value of -$5.6 million for FY2024, which is 2284.43% up from last year.
  • Regenerative Medical Technology's Net Income towards Common Stockholders amounted to -$3.9 million in Q3 2025, which was down 34436.35% from -$1.3 million recorded in Q2 2025.
  • In the past 5 years, Regenerative Medical Technology's Net Income towards Common Stockholders ranged from a high of $68663.0 in Q4 2022 and a low of -$9.9 million during Q3 2021
  • Over the past 5 years, Regenerative Medical Technology's median Net Income towards Common Stockholders value was -$758890.0 (recorded in 2025), while the average stood at -$1.5 million.
  • As far as peak fluctuations go, Regenerative Medical Technology's Net Income towards Common Stockholders soared by 10439.81% in 2022, and later tumbled by 39913110.6% in 2023.
  • Regenerative Medical Technology's Net Income towards Common Stockholders (Quarter) stood at -$1.6 million in 2021, then surged by 104.4% to $68663.0 in 2022, then plummeted by 2675.25% to -$1.8 million in 2023, then soared by 63.86% to -$639071.0 in 2024, then crashed by 516.01% to -$3.9 million in 2025.
  • Its Net Income towards Common Stockholders stands at -$3.9 million for Q3 2025, versus -$1.3 million for Q2 2025 and -$758890.0 for Q1 2025.